Nanjing Vazyme Biotech Co Ltd
SSE:688105
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nanjing Vazyme Biotech Co Ltd
Short-Term Debt
Nanjing Vazyme Biotech Co Ltd
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nanjing Vazyme Biotech Co Ltd
SSE:688105
|
Short-Term Debt
¥554.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Short-Term Debt
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Short-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Short-Term Debt
¥1.2B
|
CAGR 3-Years
116%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Short-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Short-Term Debt
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nanjing Vazyme Biotech Co Ltd
Glance View
Nanjing Vazyme Biotech Co., Ltd. is an intriguing player in the biotechnology sector, having carved a niche in the research, development, and production of an array of innovative biological reagents and solutions. Established in the vibrant city of Nanjing, this company stands at the crossroads of science and commerce, offering products that span across PCR reagents, protein engineering, and enzyme solutions. Their expertise is rooted in leveraging cutting-edge molecular biology, allowing the company to cater to a diverse clientele that includes academic research institutions, healthcare providers, and industries that require precise biochemical testing and analysis. Vazyme's growth story is intertwined with the fields of molecular diagnostics and life sciences, industries that have seen rapid advancements and heightened demand, especially in recent years. The company generates revenue predominantly through the sale of high-quality reagents that are essential for the accurate and reliable processing of biological data. By continually incorporating the latest scientific breakthroughs into their products, they ensure that their solutions remain at the forefront of the market. This strategy not only enhances their competitive edge but also solidifies customer loyalty and expands their market presence across the globe, establishing Vazyme as a key contributor to the biotechnology landscape.
See Also
What is Nanjing Vazyme Biotech Co Ltd's Short-Term Debt?
Short-Term Debt
554.3m
CNY
Based on the financial report for Dec 31, 2024, Nanjing Vazyme Biotech Co Ltd's Short-Term Debt amounts to 554.3m CNY.
What is Nanjing Vazyme Biotech Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 5Y
73%
Over the last year, the Short-Term Debt growth was -51%.